Antibiotic policy in critically ill patients

Intensive and Critical Care Medicine: WFSICCM World Federation of Societies of Intensive and Critical Care Medicine

Volumn , Issue , 2009, Pages 237-249

  Lerma, Francisco Álvarez ^a   Martínez, Mercedes Palomar ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892263216     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-1436-7_20     Document Type: Chapter

References (61)

1. Alvarez-Lerma F, ICU-Acquired Pneumonia Study Group (1996) Modification of empiric antibiotic treatment in patients with pneumonia acquired in intensive care unit. Intensive Care Med 22:387-394
2. Luna CL, Vujacich P, Niederman MS et al (1997) Impact of BAL data on the therapy ant outcome of ventilator-associated pneumonia. Chest 111:676-685
3. Kollef MH (1999) Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 115:462-474
4. Ibrahim EH, Sherman G, Ward S et al (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155
5. Rahal JJ, Urban C, Horn D et al (1998) Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 14:1233-1237
6. Fridkin SK, Edwards JR, Tenover FC et al (2001) Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project. National Nosocomial Infections Surveillance (NNIS) System Hospitals. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 33:324-330
7. American College of Chest Physicians and Society of Critical Care Medicine Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 20:864-874
8. European Society of Intensive Care Medicine (1994) The problem of sepsis?An expert report of the European Society of Intensive Care Medicine. Intensive Care Med 20:300-304
9. Vandenbroucke-Grauls CMJE, Vandenbroucke JP (1991) Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet 338:859-862
10. Digestive Tract Trialists? Collaborative Group (1993) Meta-analysis of randomised controlled trials of selective decontamination of the digestive tract. Selective decontamination of the digestive tract trials. Br Med J 307:525-532
11. Kollef MH (1994) The role of selective digestive tract decontamination on mortality and respiratory tract infections. A meta-analysis. Chest 105:1101-1108
12. Silvestri L, van Saene HK, Milanese M et al (2007) Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect 65(3):187-203
13. Silvestri L, van Saene HK, Thomann C, Peri? M (2007) Selective decontamination of the digestive tract reduces pneumonia and mortality without resistance emerging. Am J Infect Control 35:354-357
14. Sirvent JM, Torres A, El-Ebiary M et al (1997) Prospective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. Am J Respir Crit Care Med 155:1729-1734
15. Safdar N, Said A, Lucey MR (2004) The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: A systematic review and metaanalysis. Liver Transpl 10:817-827
16. Tetteroe GW, Wagenvoort JH, Castelein A et al (1990) Selective decontamination to reduce gram-negative colonization and infections after aesophageal resection. Lancet 335:704-707
17. Nathens AB, Marshall JC (1999) Selective decontamination of digestive tract in surgical patients. A systematic review of the evidence. Arch Surg 134:170-176
18. Pederzoli P, Bassi C, Vesentini S, Campedelli A (1993) A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 176:480-483
19. Dellinger EP, Tellado JM, Soto NE et al (2007) Early antibiotic treatment for severe acute necrotizing pancreatitis: A randomized, double-blind, placebo-controlled study. Ann Surg 245:674-683
20. Jorda R, Parras F, Ibanez J et al (1993) Diagnosis of nosocomial pneumonia in mechanically ventilated patients by the blind protected telescoping catheter. Intensive Care Med 19:377-383
21. Pugin J, Auckenthaler R, Mili A et al (1991) Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 143:1121-1129
22. Sanchez Carrillo C, Guerrero Gomez C (2003) Recogida, transporte y procesamiento general de muestras de laboratorio de Microbiologia. In: Cercenado E, Canton R (eds) Procedimientos de microbiologia clinica. Recomendaciones de la Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica (SEIMC). http://Www.seimc.org/documentos/protocolos/microbiologia/
23. Ribes JA, Limper AH, Espy MJ, Smith TF (1997) PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: Analysis of sensitivity and specificity. J Clin Microbiol 35:830-835
24. Sandhu GS, Kline BC, Stockman L, Roberts GD (1995) Molecular probes for diagnosis of fungal infections. J Clin Microbiol 33:2913-2919
25. Coll P, Coque MT, Dominguez MA et al (2005) Metodos moleculares de tipificacion epidemiologica en bacteriologia. In: Cercenado E, Canton R (eds) Procedimientos de microbiologia clinica. Recomendaciones de la Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica (SEIMC). http://www.seimc.org/documentos/protocolos/microbiologia/
26. Fink MP, Snydman DR, Niederman MS et al (1994) Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 38:547-557
27. Menendez R, Perpina M, Torres A (2003) Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect 18:103-111
28. Pea F, Furlanut M (2001) Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 40:833-868
29. Foxworth J (1997) Recognizing and preventing antibiotic-associated complications in the critical care setting. Crit Care Nurs Q 20:1-11
30. Joannidis M (2004) Drug-induced renal failure in the ICU. Int J Artif Organs 27:1034-1042
31. Debord J, Voultoury JC, Lachatre G et al (1994) Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients. Int J Biomed Comput 36:135-137
32. Dworzak DL, Pugsley MP, Sanders CL, Horowitt EA (1987) Emergence of resistance in Gramnegative bacteria during therapy with extended-spectrum cephalosporin. Eur J Clin Microbiol 6:456-459
33. Neuhauser MM, Weinstein RA, Rydman R et al (2003) Antibiotic resistance among Gramnegative bacilli in US Intensive Care Units. Implications for fluoroquinolone use. JAMA 289:885-888
34. Akinci E, Colpan A, Bodur H et al (2005) Risk factors for ICU-acquired imipenem-resistant gram-negative bacterial infections. J Hosp Infect 59:317-323
35. Meyer E, Schwab F, Gastmeier P et al (2006) Stenotrophomonas maltophilia and antibiotic use in German intensive care units: Data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units). J Hosp Infect 64:238-243
36. Chastre J, Wolff M, Fagon JY et al (2003) Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588-2598
37. Kollef MH (2001) Hospital-acquired pneumonia and de-escalation of antimicrobial treatment. Crit Care Med 29:1473-1475
38. Ibrahim EH, Ward S, Sherman G et al (2001) Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 29(6):1109-1115
39. Rello J, Vidaur L, Sandiumenge A et al (2004) De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 32(11):2183-2190
40. Alvarez-Lerma F, Alvarez B, Luque P et al (2006) Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: A prospective observational study. Crit Care 10:R78
41. Leone M, Garcin F, Bouvenot J et al (2007) Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 35:379-385
42. Giantsou E, Liratzopoulos N, Efraimidou E et al (2007) De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 33:1533-1540
43. Gerding DN, Larson TA, Hughes RA et al (1991) Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 35:1284-1290
44. Kollef MH, Vlasnik J, Sharpless L et al (1997) Scheduled change of antibiotic classes. A strat- egy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 156:1040-1048
45. Gruson D, Hibert G, Vargas F et al (2000) Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 162:837-843
46. Hughes MG, Evans HL, Chong TW et al (2004) Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 32:53-60
47. Merz LR, Warren DK, Kollef MH, Fraser VJ (2004) Effects of an antibiotic cycling program on antibiotic prescribing practices in an intensive care unit. Anitmicrob Agents Chemother 48:2861-2865
48. Martinez JA, Nicolas JM, Marco F et al (2006) Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 34(2):329-336
49. Sandiumenge A, Diaz E, Rodriguez A et al (2006) Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 57:1197-1204
50. Brown E, Nathwani D (2005) Antibiotic cycling or rotation: A systematic review of the evidence of efficacy. J Antimicrob Chemother 55:6-9
51. Masterton RG (2005) Antibiotic cycling: more than it might seem? J Antimicrob Chemother 55:1-5
52. Kollef MH (2006) Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the Intensive Care Unit? Clin Infect Dis 43(Suppl 2):S82-S88.)
53. Maertens J, Theunissen K, Verhoef G et al (2005) Galactomannan and computed tomographybased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 41:1242-1250
54. Pittet D, Monod M, Suter PM et al (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751-758
55. Leon C, Ruiz-Santana S, Saavedra P et al (2006) A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730-737
56. Blondeu JM, Hansen G, Metzler K, Hedlin P (2004) The role of PK/PD parameters to avoid and increase of resistance: Mutant prevention concentration. J Chemother 16(Suppl) 3:1-19
57. Preston SL, Drusano GL, Berman AL et al (1998) Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:159-160
58. Forrest A, Nix DE, Ballow CH et al (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081
59. Thomas JK, Forrest A, Bhavnani SM et al (1998) Pharmacodynamic evaluation of factors associated with development of bacteria resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42:521-527
60. Pea F, Furlanut M (2001) Pharmacokinetic aspects of treating infections in the intensive care unit: Focus on drug interactions. Clin Pharmacokinet 40:833-868
61. Grau S, Alvarez-Lerma F, Dominguez-Gil A (2007) Pharmacokinetic/ pharmacodynamic indices: are we ready to use them in daily practice? Expert Rev Anti Infect Ther 5:913-916